Kim Insook, Crippen Gordon M, Amidon Gordon L
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109-1065, USA.
Mol Pharm. 2004 Nov-Dec;1(6):434-46. doi: 10.1021/mp049959+.
Biphenyl hydrolase-like (BPHL) protein is a novel serine hydrolase which has been identified as human valacyclovirase (VACVase), catalyzing the hydrolytic activation of valine ester prodrugs of the antiviral drugs acyclovir and ganciclovir as well as other amino acid ester prodrugs of therapeutic nucleoside analogues. The broad specificity for nucleoside analogues as parent drugs suggests that BPHL may be particularly useful as a molecular target for prodrug activation. In order to develop an initial structural view of the specificity of BPHL, a homology model of BPHL based on the crystal structure of 2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase was developed using the Molecular Operating Environment package (Chemical Computing Group, Montreal, Quebec), evaluated for its stereochemical quality and identification of free cysteines, and used in a molecular docking study. The BPHL model has residues S122, H255, and D227 comprising the putative catalytic triad in proximity and potential charge-charge interaction sites, M52 or D123 for the alpha-amino group. The model also suggested that the structural preference of BPHL for hydrophobic amino acyl promoieties and its limited activity for the secondary alcohol substrates may be attributed to the hydrophobic acyl-binding site formed by residues I158, G161, I162, and L229, and the spatial constraint around the catalytic site by a loop on one side, the active serine and histidine on the other side, and L53 and L179 on top. In addition, the broad specificity for nucleoside analogues may be due to the relatively less constrained nucleoside-binding site opening toward the entrance of the substrate-binding pocket. The homology model of BPHL provides a basis for further investigation of the catalytic and active site residues, can account for the observed structure activity profile of BPHL, and will be useful in the design of nucleoside prodrugs.
类联苯水解酶(BPHL)蛋白是一种新型丝氨酸水解酶,已被鉴定为人伐昔洛韦酶(VACVase),可催化抗病毒药物阿昔洛韦和更昔洛韦的缬氨酸酯前药以及治疗性核苷类似物的其他氨基酸酯前药的水解活化。对核苷类似物作为母体药物具有广泛的特异性表明,BPHL作为前药活化的分子靶点可能特别有用。为了初步了解BPHL特异性的结构,使用分子操作环境软件包(化学计算集团,蒙特利尔,魁北克)基于2-羟基-6-氧代-7-甲基辛-2,4-二烯酸水解酶的晶体结构构建了BPHL的同源模型,评估了其立体化学质量并鉴定了游离半胱氨酸,并用于分子对接研究。BPHL模型中,残基S122、H255和D227构成了假定的催化三联体,且位置相邻,还有用于α-氨基的潜在电荷-电荷相互作用位点M52或D123。该模型还表明,BPHL对疏水性氨基酰前体部分的结构偏好及其对仲醇底物的有限活性可能归因于由残基I158、G161、I162和L229形成的疏水性酰基结合位点,以及催化位点一侧的环、另一侧的活性丝氨酸和组氨酸以及顶部的L53和L179所造成的空间限制。此外,对核苷类似物的广泛特异性可能是由于核苷结合位点向底物结合口袋入口处开放的限制相对较少。BPHL的同源模型为进一步研究催化和活性位点残基提供了基础,能够解释观察到的BPHL的结构活性特征,并将有助于核苷前药的设计。